Light Chain Bioscience (Novimmune)
Develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
$119—178m (Dealroom.co estimates Jan 2016.)
Company register number CH-660.0.428.998-8
Geneva Canton of Geneva (HQ)
Financials
Estimates*
EUR | 2015 |
---|---|
Revenues | 13.9m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$14.0m | Series A | ||
$46.0m | Series B | ||
N/A | N/A | Early VC | |
$54.8m | Series C | ||
N/A | $22.4m | Series D | |
N/A | N/A | Early VC | |
N/A | €6.0m | Grant | |
$66.0m | Series E | ||
* | €27.0m | Series F | |
Total Funding | $240m |
Related Content
Recent News about Light Chain Bioscience (Novimmune)
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.